Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

Results of the Hyper-CVAD Regimen in Elderly Acute Lymphocytic Leukemia (ALL)

Susan O’Brien, M.D., Deborah Thomas, MD, Farhad Ravandi-Kashani, Stefan Faderl, Sherry Pierce, Hagop Kantarjian

Blood (2008) 112 (11): 3954.

https://doi.org/10.1182/blood.V112.11.3954.3954

Published: 2008

Journal Articles

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

Susan O’Brien, M.D., Deborah Thomas, MD, Farhad Ravandi-Kashani, Stefan Faderl, Jorge Cortes, Gautam Borthakur, Sherry Pierce, Guillermo Garcia- Manero, Hagop Kantarjian

Blood (2008) 112 (11): 3966.

https://doi.org/10.1182/blood.V112.11.3966.3966

Published: 2008

Journal Articles

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Gautam Borthakur, MD, Marcos de Lima, MD, Hagop Kantarjian, MD, Lianchun Xiao, MS, Leandro de Padua Silva, MD, Guillermo Garcia-Manero, MD, Sergio Giralt, MD, Farhad Ravandi-Kashani, MD, Sherry Pierce, Richard Champlin, MD

Blood (2008) 112 (11): 3302.

https://doi.org/10.1182/blood.V112.11.3302.3302

Published: 2008

Journal Articles

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

Jean-Pierre Issa, Ryan Castoro, Farhad Ravandi-Kashani, Stefan Faderl, Xuelin Huang, Elihu Estey, Gautam Borthakur, Gail Morris, Guillermo Garcia-Manero, Hagop M Kantarjian

Blood (2008) 112 (11): 228.

https://doi.org/10.1182/blood.V112.11.228.228

Published: 2008

Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.

Blood (2007) 110 (11): 1851.

https://doi.org/10.1182/blood.V110.11.1851.1851

Published: 2007

Journal Articles

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Srdan Verstovsek, MD, PhD, Ayalew Tefferi, M.D., Steven Kornblau, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3543.

https://doi.org/10.1182/blood.V110.11.3543.3543

Published: 2007

Journal Articles

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

Nitin Jain, MD, Gloria N. Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Guillermo Garcia-Manero, MD, Farhad Ravandi-Kashani, MD, Sherry Pierce, Gautam Borthakur, MD, Susan O’Brien, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 2858.

https://doi.org/10.1182/blood.V110.11.2858.2858

Published: 2007

Journal Articles

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Susan O’Brien, MD

Blood (2007) 110 (11): 2824.

https://doi.org/10.1182/blood.V110.11.2824.2824

Published: 2007

Journal Articles

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Jorge Cortes, MD, Stefan Faderl, MD, Farhad Ravandi-Kashani, MD, William Wierda, MD, PhD, Alma Rodriguez, MD, Luis Fayad, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2825.

https://doi.org/10.1182/blood.V110.11.2825.2825

Published: 2007

Journal Articles

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

Stefan Faderl, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Susan O’Brien, MD, Farhad Ravandi-Kashani, MD, Luis Fayad, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Mary L. Browning RN, Michael J. Keating MB, BS

Blood (2006) 108 (11): 2827.

https://doi.org/10.1182/blood.V108.11.2827.2827

Published: 2006

Journal Articles

The Clinical Significance of Biphenotypia in Blastic Phase CML.

Constantine S. Tam, MBBS, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, William G. Wierda, MD PhD, Jenny Shan, PhD, Joselle Otero-Palacios, BSc, Ahmed Awais, MD, Farhad Ravandi-Kashani, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 4785.

https://doi.org/10.1182/blood.V108.11.4785.4785

Published: 2006

Journal Articles

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Farhad Ravandi-Kashani, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Miloslav Beran, MD, Sherry Pierce, RN, Charles A. Koller, MD, Jorge Cortes, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 4830.

https://doi.org/10.1182/blood.V108.11.4830.4830

Published: 2006

Journal Articles

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Charles Asa Koller, MD, Miloslav Beran, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Dan Jones, MD, PhD, Susan O’Brien, MD

Blood (2006) 108 (11): 1861.

https://doi.org/10.1182/blood.V108.11.1861.1861

Published: 2006

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

William G. Wierda, MD, PhD, Susan O’Brien, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Jorge Cortes, MD, Francis Giles, MD, Michael Andreeff, MD, PhD, Charles Asa Koller, MD, Susan Lerner, MS, RHIA, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS

Blood (2006) 108 (11): 31.

https://doi.org/10.1182/blood.V108.11.31.31

Published: 2006

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

Journal Articles

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Ricardo H. Alvarez, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, Francis Giles, MD, Susan O’Brien, MD, Charles Asa Koller, MD, Stefan Faderl, MD, Deborah Thomas, MD, John J. Wright, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 1999.

https://doi.org/10.1182/blood.V108.11.1999.1999

Published: 2006

Journal Articles

Combination Therapy with Alemtuzumab and Pentostatin Is Effective and Has Acceptable Toxicity in Patients with T-Lymphoid Neoplasms.

Farhad Ravandi-Kashani, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Charles Koller, MD, Shirley Odinga, RN, William Wierda, MD, Gautam Borthakur, MD, Dan Jones, MD, Francis Giles, MD, Susan O’Brien, MD, Michael Keating, MD

Blood (2006) 108 (11): 4971.

https://doi.org/10.1182/blood.V108.11.4971.4971

Published: 2006

Journal Articles

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Alfonso Quintas-Cardama, MD, Ayalew Tefferi, M.D., Jorge Cortes, M.D., Animesh Pardanani, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Pat Ault, R.N., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4902.

https://doi.org/10.1182/blood.V108.11.4902.4902

Published: 2006

Journal Articles

Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.

Gautam Borthakur, Farhad Ravandi-Kashani, Jorge Cortes, Elias Jabbour, Stefan Faderl, Susan O’Brien, Srdan Verstovsek, Guillermo Garcia-Manero, Beth Ann Newman, Francis Giles, Jean-Pierre Issa, Hagop M. Kantarjian

Blood (2006) 108 (11): 518.

https://doi.org/10.1182/blood.V108.11.518.518

Published: 2006

NARROW

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Results of the Hyper-CVAD Regimen in Elderly Acute Lymphocytic Leukemia (ALL)

Outcome of Adults with Acute Lymphocytic Leukemia (ALL) with Second Salvage Therapy

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL).

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

The Clinical Significance of Biphenotypia in Blastic Phase CML.

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Combination Therapy with Alemtuzumab and Pentostatin Is Effective and Has Acceptable Toxicity in Patients with T-Lymphoid Neoplasms.

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only